Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2009 Publisher: Sanofi-aventis, One Onslow Street, Guildford, Surrey, GU1 4YS, UK
Anticholinesterase. Post-operative urinary retention. Post operative ileus and intestinal atony. To assist emptying of the neurogenic bladder. As an adjunct in the treatment of myasthenia gravis.
One Ubretid tablet daily, half an hour before breakfast.
One Ubretid tablet daily or on alternate days, half an hour before breakfast, on an empty stomach.
Dosage to be individualised for each patient, dependent upon the severity of the condition, the degree and duration of response and the side effects encountered. The tablets should always be taken on an empty stomach half an hour before breakfast. Dosage should commence at 1 tablet daily and may be adjusted at intervals of three to four days to a total not exceeding 4 tablets daily.
Up to 2 tablets daily according to age.
No dosage adjustment is necessary for elderly patients.
Ubretid tablets are for oral administration.
Overdosage of Ubretid may also produce skeletal muscle fatigue, weakness and eventually paralysis. The muscarinic effects of overdosage may be controlled with atropine 2mg intramuscularly repeated at intervals indicated by the clinical response until signs of mild atropinisation (dry mouth, mydriasis) appear. The patient should be kept fully atropinised for at least 24 hours.
36 months.
Store in a dry place below 25oC.
Blisters of 20μm aluminium foil and 250μm UPVC/PVdC opaque white film containing 30 tablets.
None.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
